Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2022

Schedule of Revenue from Segments to Consolidated

The following tables present our segment information (in thousands):


	Evolent Health Services		Clinical Solutions		Intersegment Eliminations		Subtotal		Corporate (1)		Consolidated Total
Revenue
For the Three Months Ended September 30, 2022
Total revenue	$	107,033	$	245,257	$	295	$	352,585	$	—	$	352,585

For the Three Months Ended September 30, 2021
Total revenue	$	63,315	$	159,614	$	(458)	$	222,471	$	—	$	222,471


	Evolent Health Services		Clinical Solutions		Subtotal		Corporate (1)		Consolidated Total
For the Three Months Ended September 30, 2022
Adjusted EBITDA	$	18,507	$	16,303	$	34,810	$	(6,755)	$	28,055

For the Three Months Ended September 30, 2021
Adjusted EBITDA	$	(3,353)	$	23,883	$	20,530	$	(6,765)	$	13,765


	Evolent Health Services		Clinical Solutions		Intersegment Eliminations		Subtotal		Corporate (1)		Consolidated Total
Revenue
For the Nine Months Ended September 30, 2022
Total revenue	$	307,147	$	663,060	$	(626)	$	969,581	$	—	$	969,581

For the Nine Months Ended September 30, 2021
Total revenue	$	223,924	$	437,031	$	(1,356)	$	659,599	$	—	$	659,599

	Evolent Health Services		Clinical Solutions		Subtotal		Corporate (1)		Consolidated Total
For the Nine Months Ended September 30, 2022
Adjusted EBITDA	$	41,854	$	51,988	$	93,842	$	(19,793)	$	74,049

For the Nine Months Ended September 30, 2021
Adjusted EBITDA	$	9,120	$	53,456	$	62,576	$	(20,558)	$	42,018

————————

(1)Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.

Schedule of Reconciliation of Adjusted EBITDA to Net Loss

The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2022		2021		2022		2021
Net income (loss) attributable to common shareholders of Evolent Health, Inc.	$	2,123	$	(13,040)	$	(7,815)	$	(31,954)
Less:
Interest income	425		120		765		311
Interest expense	(4,754)		(6,367)		(9,143)		(18,978)
Benefit from (provision for) income taxes	45,516		(234)		44,498		(936)
Change in tax receivable agreement liability	(42,870)		—		(42,870)		—
Depreciation and amortization expenses	(17,196)		(14,859)		(47,414)		(44,962)
Gain on transfer of membership	—		—		—		22,969
Loss on extinguishment/repayment of debt, net	(10,192)		—		(10,192)		(19,158)
Gain from equity method investees	1,392		63		3,940		12,725
Change in fair value of contingent consideration	12,700		225		5,822		819
Other income (expense), net	(345)		(41)		130		(73)
Repositioning costs	—		—		—		(6,043)
Stock-based compensation expense	(6,992)		(4,395)		(19,350)		(11,754)
Severance costs	(996)		—		(1,035)		(52)
Amortization of contract cost assets	(25)		(110)		(79)		(433)
Strategy and shareholder advisory expenses	—		—		—		(6,513)
Acquisition costs	(2,595)		(1,207)		(6,473)		(3,277)
Gain (loss) from discontinued operations (1)	—		—		(463)		1,383
Adjusted EBITDA	$	28,055	$	13,765	$	74,049	$	42,018

————————

(1)Includes $(0.5) million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $1.9 million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively.